MECOM is altered in 1.36% of acute myeloid leukemia patients [3].

MECOM is an inclusion criterion in 164 clinical trials for acute myeloid leukemia, of which 118 are open and 46 are closed. Of the trials that contain MECOM status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 59 are phase 1 (44 open), 30 are phase 1/phase 2 (22 open), 59 are phase 2 (42 open), 3 are phase 2/phase 3 (2 open), 10 are phase 3 (7 open), and 1 is no phase specified (0 open) [4].

MECOM is altered in 0.82% of myelodysplastic syndromes patients [3].

MECOM is an inclusion criterion in 154 clinical trials for myelodysplastic syndromes, of which 122 are open and 32 are closed. Of the trials that contain MECOM status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 60 are phase 1 (46 open), 29 are phase 1/phase 2 (26 open), 48 are phase 2 (36 open), 2 are phase 2/phase 3 (1 open), 10 are phase 3 (10 open), and 3 are no phase specified (2 open) [4].

MECOM is an inclusion criterion in 54 clinical trials for acute lymphoblastic leukemia, of which 38 are open and 16 are closed. Of the trials that contain MECOM status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 17 are phase 1 (10 open), 6 are phase 1/phase 2 (6 open), 25 are phase 2 (18 open), 1 is phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 34 clinical trials for chronic myelomonocytic leukemia, of which 30 are open and 4 are closed. Of the trials that contain MECOM status and chronic myelomonocytic leukemia as inclusion criteria, 12 are phase 1 (10 open), 8 are phase 1/phase 2 (8 open), 12 are phase 2 (10 open), and 2 are phase 3 (2 open) [4].

MECOM is an inclusion criterion in 33 clinical trials for chronic myeloid leukemia, of which 23 are open and 10 are closed. Of the trials that contain MECOM status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 11 are phase 1 (7 open), 7 are phase 1/phase 2 (7 open), 13 are phase 2 (9 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 23 clinical trials for hodgkin lymphoma, of which 14 are open and 9 are closed. Of the trials that contain MECOM status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 1 is no phase specified (0 open) [4].

MECOM is altered in 0.84% of multiple myeloma patients [3].

MECOM is an inclusion criterion in 21 clinical trials for multiple myeloma, of which 16 are open and 5 are closed. Of the trials that contain MECOM status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (8 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].

MECOM is altered in 2.63% of non-hodgkin lymphoma patients [3].

MECOM is an inclusion criterion in 20 clinical trials for non-hodgkin lymphoma, of which 13 are open and 7 are closed. Of the trials that contain MECOM status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 8 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (7 open) [4].

MECOM is an inclusion criterion in 17 clinical trials for acute biphenotypic leukemia, of which 11 are open and 6 are closed. Of the trials that contain MECOM status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 17 clinical trials for myelofibrosis, of which 12 are open and 5 are closed. Of the trials that contain MECOM status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 2 are phase 3 (2 open) [4].

MECOM is an inclusion criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 10 are open and 4 are closed. Of the trials that contain MECOM status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 6 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [4].

MECOM is an inclusion criterion in 14 clinical trials for primary myelofibrosis, of which 12 are open and 2 are closed. Of the trials that contain MECOM status and primary myelofibrosis as inclusion criteria, 4 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (2 open), and 4 are phase 3 (4 open) [4].

MECOM is an inclusion criterion in 11 clinical trials for Burkitt lymphoma, of which 6 are open and 5 are closed. Of the trials that contain MECOM status and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 11 clinical trials for mantle cell lymphoma, of which 6 are open and 5 are closed. Of the trials that contain MECOM status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 11 clinical trials for myeloproliferative neoplasm, of which 7 are open and 4 are closed. Of the trials that contain MECOM status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 6 are phase 2 (4 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 11 clinical trials for secondary acute myeloid leukemia, of which 11 are open and 0 are closed. Of the trials that contain MECOM status and secondary acute myeloid leukemia as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (6 open) [4].

MECOM is altered in 1.36% of acute leukemia patients [3].

MECOM is an inclusion criterion in 10 clinical trials for acute leukemia, of which 5 are open and 5 are closed. Of the trials that contain MECOM status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 10 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 10 are open and 0 are closed. Of the trials that contain MECOM status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 9 are phase 2 (9 open) [4].

MECOM is an inclusion criterion in 10 clinical trials for anaplastic large cell lymphoma, of which 6 are open and 4 are closed. Of the trials that contain MECOM status and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

MECOM is altered in 2.63% of follicular lymphoma patients [3].

MECOM is an inclusion criterion in 9 clinical trials for follicular lymphoma, of which 5 are open and 4 are closed. Of the trials that contain MECOM status and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 9 clinical trials for marginal zone lymphoma, of which 5 are open and 4 are closed. Of the trials that contain MECOM status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 9 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 8 are open and 1 is closed. Of the trials that contain MECOM status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (0 open), and 4 are phase 3 (4 open) [4].

MECOM is an inclusion criterion in 9 clinical trials for polycythemia vera, post-polycythemic myelofibrosis phase, of which 8 are open and 1 is closed. Of the trials that contain MECOM status and polycythemia vera, post-polycythemic myelofibrosis phase as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (0 open), and 4 are phase 3 (4 open) [4].

MECOM is an inclusion criterion in 8 clinical trials for refractory anemia with excess blasts, of which 6 are open and 2 are closed. Of the trials that contain MECOM status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 4 are phase 2 (3 open) [4].

MECOM is an inclusion criterion in 8 clinical trials for therapy-related acute myeloid leukemia, of which 8 are open and 0 are closed. Of the trials that contain MECOM status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 7 are phase 2 (7 open) [4].

MECOM is an inclusion criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain MECOM status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].

MECOM is an inclusion criterion in 7 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 6 are open and 1 is closed. Of the trials that contain MECOM status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

MECOM is altered in 2.78% of lymphoma patients [3].

MECOM is an inclusion criterion in 6 clinical trials for lymphoma, of which 4 are open and 2 are closed. Of the trials that contain MECOM status and lymphoma as inclusion criteria, 3 are phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

MECOM is altered in 0.96% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [3].

MECOM is an inclusion criterion in 6 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 3 are open and 3 are closed. Of the trials that contain MECOM status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 6 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 1 is closed. Of the trials that contain MECOM status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [4].

MECOM is an inclusion criterion in 6 clinical trials for prolymphocytic leukemia, of which 4 are open and 2 are closed. Of the trials that contain MECOM status and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 6 clinical trials for therapy-related myelodysplastic syndrome, of which 6 are open and 0 are closed. Of the trials that contain MECOM status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].

MECOM is an inclusion criterion in 5 clinical trials for lymphoblastic lymphoma, of which 4 are open and 1 is closed. Of the trials that contain MECOM status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

MECOM is an inclusion criterion in 5 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain MECOM status and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (2 open) and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 5 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 3 are closed. Of the trials that contain MECOM status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (1 open) [4].

MECOM is an inclusion criterion in 5 clinical trials for secondary myelodysplastic syndrome, of which 4 are open and 1 is closed. Of the trials that contain MECOM status and secondary myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

MECOM is an inclusion criterion in 5 clinical trials for secondary myelofibrosis, of which 4 are open and 1 is closed. Of the trials that contain MECOM status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 2 (2 open) [4].

MECOM is an inclusion criterion in 5 clinical trials for small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain MECOM status and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MECOM is altered in 1.49% of B-cell non-hodgkin lymphoma patients [3].

MECOM is an inclusion criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain MECOM status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

MECOM is altered in 1.38% of diffuse large B-cell lymphoma patients [3].

MECOM is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain MECOM status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (2 open) [4].

MECOM is an inclusion criterion in 4 clinical trials for acute undifferentiated leukemia, of which 4 are open and 0 are closed. Of the trials that contain MECOM status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].

MECOM is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain MECOM status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [4].

MECOM is an inclusion criterion in 4 clinical trials for plasma cell leukemia, of which 2 are open and 2 are closed. Of the trials that contain MECOM status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [4].

MECOM is an inclusion criterion in 3 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain MECOM status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 3 clinical trials for blastic plasmacytoid dendritic cell neoplasm, of which 3 are open and 0 are closed. Of the trials that contain MECOM status and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 3 clinical trials for refractory anemia, of which 2 are open and 1 is closed. Of the trials that contain MECOM status and refractory anemia as inclusion criteria, 3 are phase 2 (2 open) [4].

MECOM is an inclusion criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain MECOM status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

MECOM is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MECOM status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [4].

MECOM is altered in 5.6% of T-cell non-hodgkin lymphoma patients [3].

MECOM is an inclusion criterion in 2 clinical trials for T-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MECOM is altered in 4.96% of mature T-cell and NK-cell neoplasm patients [3].

MECOM is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

MECOM is altered in 1.73% of malignant solid tumor patients [3].

MECOM is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for acute bilineal leukemia, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and acute bilineal leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (0 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for acute promyelocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for chronic myelomonocytic leukemia-1, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (1 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain MECOM status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for refractory anemia with excess blasts-1, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and refractory anemia with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for small lymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and small lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) [4].

MECOM is altered in 6.67% of indolent non-hodgkin lymphoma patients [3].

MECOM is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is altered in 5.6% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

MECOM is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MECOM is altered in 4.43% of T-cell and NK-cell neoplasm patients [3].

MECOM is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is altered in 1.2% of neuroblastoma patients [3].

MECOM is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MECOM is altered in 0.92% of rhabdomyosarcoma patients [3].

MECOM is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MECOM is altered in 1.9% of hematopoietic and lymphoid malignancy patients [3].

MECOM is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is altered in 1.15% of leukemia patients [3].

MECOM is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is altered in 0.84% of plasma cell neoplasm patients [3].

MECOM is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for aggressive non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and aggressive non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for B-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-0, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and chronic myelomonocytic leukemia-0 as inclusion criteria, 1 is no phase specified (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 3 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for NK-cell lymphoma, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and NK-cell lymphoma, unclassifiable as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for refractory anemia with ring sideroblasts, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and refractory anemia with ring sideroblasts as inclusion criteria, 1 is phase 2 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and systemic mastocytosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for therapy-related myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and therapy-related myeloid neoplasm as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

MECOM is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [4].